1026200-27-0

Basic information

• Product Name: L-Valine, 3-Methyl-N-[[[(1R,2R)-2-(4-penten-1-yl)cyclopropyl]oxy]carbonyl]-
• Synonyms: L-Valine, 3-Methyl-N-[[[(1R,2R)-2-(4-penten-1-yl)cyclopropyl]oxy]carbonyl]-;(S)-3,3-dimethyl-2-((((1R,2R)-2-(pent-4-en-1-yl)cyclopropoxy)carbonyl)amino)butanoic acid;ZWQXCSWBZGSXDK-IJLUTSLNSA-N
• CAS NO: 1026200-27-0
• Molecular Formula: C₁₅H₂₅NO₄
• Molecular Weight: 283.3633
• Mol File: 1026200-27-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: L-Valine, 3-Methyl-N-[[[(1R,2R)-2-(4-penten-1-yl)cyclopropyl]oxy]carbonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: L-Valine, 3-Methyl-N-[[[(1R,2R)-2-(4-penten-1-yl)cyclopropyl]oxy]carbonyl]-(1026200-27-0)
• EPA Substance Registry System: L-Valine, 3-Methyl-N-[[[(1R,2R)-2-(4-penten-1-yl)cyclopropyl]oxy]carbonyl]-(1026200-27-0)

Safety Data

• Hazardous Substances Data: 1026200-27-0(Hazardous Substances Data)

Usage

General Description

L-Valine, 3-Methyl-N-[[[(1R,2R)-2-(4-penten-1-yl)cyclopropyl]oxy]carbonyl]- is a compound that belongs to the group of L-amino acids, which are the building blocks of proteins. L-Valine is an essential amino acid, meaning that it cannot be produced by the body and must be obtained through dietary sources. It plays a crucial role in muscle metabolism, tissue repair, and the maintenance of nitrogen balance in the body. The chemical structure of 3-Methyl-N-[[[(1R,2R)-2-(4-penten-1-yl)cyclopropyl]oxy]carbonyl]- suggests that it could be involved in important biological processes, such as enzyme regulation or the transmission of nerve signals. The compound may have potential applications in the field of pharmaceuticals, biochemistry, and nutrition.

Upstream product

• 1206524-77-7 (1R,2R)-2-(pent-4-en-1-yl)cyclopropanol 
• 1263814-64-7 C₁₃H₁₇NO₅ 
• 124471-62-1 (E)-(hepta-1,6-dien-1-yloxy)trimethylsilane 
• 144164-32-9 methyl 3-methyl-N-(oxomethylene)-L-valinate 
• 63038-27-7 L-tert-leucine methyl ester hydrochloride 
• 1384277-05-7 trans 2-(pent-4-en-1-yl)cyclopropanol 
• 1026200-25-8 methyl 3-methyl-N-({[(1R,2R)-2-pent-4-en-1-ylcyclopropyl]oxy}carbonyl)-L-valinate 

Downstream Products

• 1350514-68-9 grazoprevir 
• 1206524-84-6 methyl (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxa-diazacyclononadecino[11,12-b]quinoxaline-8-carboxylate 
• 1206524-85-7 (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradeca-hydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid hydrate 
• 1206524-83-5 methyl (1aR,5S,8S,10R,18E,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,20,21,22,22a-dodecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylate 
• 1535212-06-6 C₃₁H₄₀F₂N₄O₇ 
• 1535212-07-7 (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1 R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,1 0,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide 
• 1206524-81-3 (2S,4R)-methyl 4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)-1-((S)-3,3-dimethyl-2-((((1R,2R)-2-(pent-4-en-1-yl)cyclopropoxy)carbonyl)amino)butanoyl)pyrrolidine-2-carboxylate 

Relevant articles and documents

INHIBITORS OF HEPATITIS C VIRUS

Compounds of Formula I are disclosed, As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors

The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.